Inflammatory breast cancer (IBC) is a serious form of cancer that demands a special treatment approach called trimodal therapy (TMT). This approach includes pre-surgery medication, a modified radical mastectomy, and radiation therapy after the surgery. While this is considered the best way to treat IBC, shockingly, only about one in three patients in the United States get this treatment. But what about other countries that are not as wealthy? The BRIDGES study aims to answer this question.

IBC is known for its aggressiveness, and early detection is crucial. However, in low- and middle-income countries (LMICs), awareness and knowledge about IBC and its treatment are often limited. This lack of awareness can lead to delayed treatment and poorer outcomes. The BRIDGES study was designed to understand how IBC is treated in these countries and to identify any gaps in care.

One of the main challenges in LMICs is the availability of healthcare resources. TMT requires advanced medical facilities and trained professionals, which might not be readily available in these regions. Additionally, the cost of treatment can be a significant barrier. Many patients in LMICs may not be able to afford the expensive medications and procedures involved in TMT.

The study highlights the need for more research and better healthcare infrastructure in LMICs. It also emphasizes the importance of educating both patients and healthcare providers about IBC. By increasing awareness and improving access to treatment, we can strive to provide better care for IBC patients worldwide.

Treating Inflammatory Breast Cancer: Challenges in Low-Income Countries

Actions